地塞米松联合利多卡因预防腹腔化疗不良反应的疗效观察

The curative effect of Dexamethasone plus Lidocaine as a prevention medicine for side effects resulting from intraperitoneal chemotherapy

目的观察地塞米松和利多卡因预防腹腔化疗不良反应的效果。方法 35例患者共行腹腔化疗146次,均在腹腔化疗的同时腹腔内注入地塞米松20 mg和利多卡因0.2 g。结果 35例患者中,仅1例出现硬化性腹膜炎,无法继续化疗,其余34例均顺利完成腹腔化疗。结论地塞米松联合利多卡因预防腹腔化疗不良反应的疗效确切,值得临床进一步推广应用。

Objective To evaluate the curative effect of Dexamethasone plus Lidocaine as a medicine for preventing side effects resulting from intraperitoneal chemotherapy.Method 35 patients were chosen as the subjects of study and subjected to 146 sessions of intraperitoneal chemotherapy.During each session, 20mg of Dexamethasone and 0.2g of Lidocaine were injected into the abdominal cavity of the patients.Finding Only one out of the 35 patients was found to contract sclerosing peritonisis and the chemotherapy for him was hence discontinued.The other 34 patients successfully went through all sessions of chemotherapy.Conclusion The study indicated that Dexamethasone plus Lidocaine can serve as an effective medicine for preventing adverse effects resulting from intraperitoneal chemotherapy.